{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-000597","form_type":"8-K","ticker":"RVMD","cik":"0001628171","company_name":"Revolution Medicines, Inc.","filed_at":"2023-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.918982+00:00","generated_at":"2026-06-20T17:07:51.958288+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Revolution Medicines reaffirms FY2022 net loss guidance of $245M–$265M","bullets":["Net loss expected to be between $245M and $265M for the year ended December 31, 2022.","Includes estimated non-cash stock-based compensation of approximately $30M to $35M.","Company also posted a corporate presentation on January 10, 2023, covering its R&D pipeline."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-000597","json":"https://secwatch.observer/filing/0000950170-23-000597.json","markdown":"https://secwatch.observer/filing/0000950170-23-000597.md","text":"https://secwatch.observer/filing/0000950170-23-000597.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628171/000095017023000597/0000950170-23-000597-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628171/000095017023000597/rvmd-20230110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:07:51.958288+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b3a101814745ebb411525adf2d37f58d47322f42","claim":"Revolution Medicines, Inc. reported the year ended December 31, 2022 results: net income between $245 million and $265 million. Guidance reaffirmed.","evidence_excerpt":"On January 10, 2023, Revolution Medicines, Inc. (the “Company”) confirmed to investors that it continues to expect that its net loss for the year ended December 31, 2022 to be between $245 million and $265 million, which includes estimated non-cash stock-based compensation expense of approximately $30 million to $35 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1628171/000095017023000597/0000950170-23-000597-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Net income","value":"between $245 million and $265 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}